BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:faricimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of faricimab\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05610319-4978@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:faricimab: Phase 4 readout est. (NCT05610319)
DESCRIPTION:faricimab\, phase 4\, Diabetic Macular Edema.\nStudy: Treat & E
 xtend Versus Fixed Dosing With Faricimab for Management of Diabetic Macula
 r Edema: A Pragmatic\, Multi-center\, Open-label\, Randomized\, Controlled
  Trial\nEstimated primary completion: December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/faricimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05610319
URL:https://assetmemo.bio/drug/faricimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06191094-4978@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:faricimab: Phase 4 readout est. (NCT06191094)
DESCRIPTION:faricimab\, phase 4.\nStudy: Pre-operative Vabysmo in Patients 
 With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic 
 Retinopathy\nEstimated primary completion: December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/faricimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06191094
URL:https://assetmemo.bio/drug/faricimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05224102-4978@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270126
DTEND;VALUE=DATE:20270127
SUMMARY:faricimab: Phase 4 readout est. (NCT05224102)
DESCRIPTION:faricimab\, phase 4\, Diabetic Macular Edema.\nStudy: A Study t
 o Investigate Faricimab Treatment Response in Treatment-Naive\, Underrepre
 sented Patients With Diabetic Macular Edema\nEstimated primary completion:
  26 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/far
 icimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05224102
URL:https://assetmemo.bio/drug/faricimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07520045-4978@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:faricimab: Phase na readout est. (NCT07520045)
DESCRIPTION:faricimab\, phase na\, Diabetic Macular Edema.\nStudy: Biomarke
 rs in Diabetic Retinopathy Treated With Faricimab vs Biosimilar Ranibizuma
 b\nEstimated primary completion: 1 June 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/faricimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07520045
URL:https://assetmemo.bio/drug/faricimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05904028-4978@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:faricimab: Phase 3 readout est. (NCT05904028)
DESCRIPTION:faricimab\, phase 3\, Age-Related Macular Degeneration.\nStudy:
  Home OCT-Guided Treatment Versus Treat and Extend for the Management of N
 eovascular AMD\nEstimated primary completion: 30 July 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/faricimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05904028
URL:https://assetmemo.bio/drug/faricimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07367282-4978@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:faricimab: Phase 4 readout est. (NCT07367282)
DESCRIPTION:faricimab\, phase 4\, Age-Related Macular Degeneration.\nStudy:
  Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-relat
 ed Macular Degeneration\nEstimated primary completion: 30 April 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/faricimab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07367282
URL:https://assetmemo.bio/drug/faricimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07695298-4978@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:faricimab: Phase 4 readout est. (NCT07695298)
DESCRIPTION:faricimab\, phase 4.\nStudy: A Prospective Longitudinal Analysi
 s of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed 
 Ocular Histoplasmosis Syndrome\nEstimated primary completion: May 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/faricimab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07695298
URL:https://assetmemo.bio/drug/faricimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06709339-4978@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:faricimab: Phase 4 readout est. (NCT06709339)
DESCRIPTION:faricimab\, phase 4.\nStudy: Study to Investigate the Efficacy\
 , Safety and Durability of Faricimab in Caucasian Patients With Polypoidal
  Choroidal Vasculopathy (MONDEGO)\nEstimated primary completion: August 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/faricimab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06709339
URL:https://assetmemo.bio/drug/faricimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07187804-4978@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280922
DTEND;VALUE=DATE:20280923
SUMMARY:faricimab: Phase 4 readout est. (NCT07187804)
DESCRIPTION:faricimab\, phase 4\, Age-Related Macular Degeneration.\nStudy:
  Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type
  3 Macular Neovascularization\nEstimated primary completion: 22 September 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/faricimab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07187804
URL:https://assetmemo.bio/drug/faricimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07403825-4978@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:faricimab: Phase 4 readout est. (NCT07403825)
DESCRIPTION:faricimab\, phase 4\, Age-Related Macular Degeneration.\nStudy:
  Efficacy of Faricimab in Patients With Subretinal Hyper-reflective Materi
 al\nEstimated primary completion: October 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/faricimab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07403825
URL:https://assetmemo.bio/drug/faricimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07425522-4978@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20281117
DTEND;VALUE=DATE:20281118
SUMMARY:faricimab: Phase 1 readout est. (NCT07425522)
DESCRIPTION:faricimab\, phase 1\, Diabetic Macular Edema.\nStudy: A Study t
 o Evaluate the Safety\, Tolerability\, Pharmacodynamics\, and Pharmacokine
 tics of RO7823653 in Participants With Diabetic Macular Edema (DME)\nEstim
 ated primary completion: 17 November 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/faricimab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07425522
URL:https://assetmemo.bio/drug/faricimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07461441-4978@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:faricimab: Phase 3 readout est. (NCT07461441)
DESCRIPTION:faricimab\, phase 3\, Age-Related Macular Degeneration.\nStudy:
  Efficacy and Durability of a Personalized Treat-and-extend Regimen of Far
 icimab for Treatment-naive Polypoidal Choroidal Vasculopathy\nEstimated pr
 imary completion: 30 November 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/faricimab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07461441
URL:https://assetmemo.bio/drug/faricimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07249216-4978@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:faricimab: Phase na readout est. (NCT07249216)
DESCRIPTION:faricimab\, phase na\, Age-Related Macular Degeneration.\nStudy
 : Identification of Molecular Signals in Vitreous Humor Associated With Su
 boptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition 
 in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical T
 rial Setting\nEstimated primary completion: June 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/faricimab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07249216
URL:https://assetmemo.bio/drug/faricimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07681167-4978@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:faricimab: Phase 2 readout est. (NCT07681167)
DESCRIPTION:faricimab\, phase 2.\nStudy: Faricimab for Chronic Central Sero
 us Chorioretinopathy: A Randomized Sham-Controlled Trial\nEstimated primar
 y completion: August 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/faricimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07681167
URL:https://assetmemo.bio/drug/faricimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07753616-4978@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:faricimab: Phase 4 readout est. (NCT07753616)
DESCRIPTION:faricimab\, phase 4\, Diabetic Macular Edema.\nStudy: South Asi
 an Patients With Diabetic Macular Oedema Treated With Faricimab Assessing 
 the Efficacy\, Durability\, and Safety (SEAFAR Study)\nEstimated primary c
 ompletion: 1 November 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/faricimab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07753616
URL:https://assetmemo.bio/drug/faricimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07922460-4978@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:faricimab: Phase 3 readout est. (NCT07922460)
DESCRIPTION:faricimab\, phase 3.\nStudy: Anti-VEGF Versus Prompt Laser or O
 bservation for Proliferative Sickle Cell Retinopathy (ALPS)\nEstimated pri
 mary completion: 1 December 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/faricimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07922460
URL:https://assetmemo.bio/drug/faricimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05844982-4978@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20291226
DTEND;VALUE=DATE:20291227
SUMMARY:faricimab: Phase 3 readout est. (NCT05844982)
DESCRIPTION:faricimab\, phase 3.\nStudy: Intravitreal Faricimab Injections 
 or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation f
 or Prevention of VA Loss Due to Radiation Retinopathy\nEstimated primary c
 ompletion: 26 December 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/faricimab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05844982
URL:https://assetmemo.bio/drug/faricimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06790784-4978@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20320229
DTEND;VALUE=DATE:20320301
SUMMARY:faricimab: Phase 3 readout est. (NCT06790784)
DESCRIPTION:faricimab\, phase 3.\nStudy: Faricimab + PRP vs. Vitrectomy + E
 ndolaser for Treatment of PDR\nEstimated primary completion: February 2032
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/faricimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06790784
URL:https://assetmemo.bio/drug/faricimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
